The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

Dupilumab is prescribed for treating moderate ... by GlobalData have expressed enthusiasm about the progress of this mechanism of action. Positive outcomes from clinical trials for both SAR444656 ...

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

However, biologics like Dupixent (dupilumab) have paved the way for ... With its innovative mechanism of action and established success in asthma, Fasenra could address critical safety and ...

In my opinion, this is the most important step, as analyzing the efficacy, safety profile, and mechanism of action ... So, sales of Dupixent (dupilumab), an IL-4/IL-13 inhibitor, in the third ...

As rilzabrutinib pleiotropically addresses the underlying immunological mechanisms of the disease ... rewarded with a broad label, the dupilumab with Type 2 inflammation and chronic bronchitis.

Targeting IL-4 receptors can address so-called Th2-mediated skin inflammation – a mechanism that the drug shares with Sanofi and Regeneron’s blockbuster AD therapy Dupixent (dupilumab ...

At that time Sanofi was cruising towards an important FDA approval for its Dupixent (dupilumab ... which has a different mechanism of action focused on IL-4. Incyte is also planning a US filing ...

Dupilumab, by binding to IL-4Rα ... The previously mentioned molecular mechanisms endorse the rationale for the development of biologic drugs with targets shared by multiple diseases. Despite common ...

Dupixent, or Dupilumab, is an FDA-approved monoclonal antibody for the treatment of eosinophilic esophagitis, or EoE, due to esophageal inflammation. It works on the mechanism of inhibiting IL-4 and ...